bluuebunny/crossref_metadata_2025_split huggingface dataset:
Multifunctional gentamicin supplementation of poly(γ‐glutamic acid)‐based hydrogels for wound dressing application
Authors: Lin Yu‐Hsin , Lin Jui‐Hsiang , Peng Shu‐Fen , Yeh Chia‐Lin , Chen Wen‐Chen , Chang Tsai‐Luan , Liu Ming‐Ju , Lai Chih‐Ho 
Published: November 2010

AbstractThe process of wound healing is composed of coagulation, inflammation, fibroplasia, collagenation, epithelization, and wound contraction. The wound dressing should protect the wound from bacterial infection, maintain a moist healing environment, and promote cell migration to reconstruct damaged tissue, and be easy to apply and remove to improve patient comfort. The purpose of our study was to develop multifunctional hydrogels composed of genipin‐crosslinked biodegradable biomaterials of poly(γ‐glutamic acid) and gelatin, encapsulating gentamicin to accelerate wound healing. The results of swelling ratio measurements clearly indicate that hydrogel composition of poly(γ‐glutamic acid)–gelatin had a higher swelling ratio and lower peel adhesion properties than gelatin hydrogel alone. In an in vitro study, the gentamicin incorporated in prepared hydrogels effectively inhibited target microorganisms and produced a higher expression of Type I collagen in fibroblast cells. Confocal laser scanning microscopy revealed that the fibroblast cells cultured in the hydrogel membranes produced fibroblast cell migration and showed a continuous lined cytoskeletal distributing status. In the in vivo study, it was found that the gentamicin incorporated in genipin‐crosslinked γ‐PGA–gelatin wound dressing demonstrates the potential of such biologically functionalized dressing to accelerate wound closure and, hence, its potential clinical usefulness. © 2010 Wiley Periodicals, Inc. J Appl Polym Sci, 2011
Facilitative production of an antimicrobial peptide royalisin and its antibody via an artificial oil‐body system
Authors: Tseng Jun‐Ming , Huang Jun‐Ru , Huang Hsiou‐Chen , Tzen Jason T. C. , Chou Wing‐Ming , Peng Chi‐Chung 
Published: November 2010

AbstractRoyalisin found in the royal jelly of Apis mellifera is an antimicrobial peptide (AMP). It has a molecular weight of 5.5 kDa, which contains six cysteine residues. In this study, royalisin was overexpressed in Escherichia coli AD494 (DE3) as two oleosin‐fusion proteins for preparation of its antibodies and functional purification. The recombinant royalisin, fused with oleosin central hydrophobic domain in both N‐ and C‐termini, was reconstituted with triacylglycerol and phospholipids to form artificial oil bodies (AOBs). The AOBs were then purified to raise the antibodies. These antibodies could recognize both the native and recombinant royalisins, but not oleosin. Another oleosin‐intein S‐fusion protein was purified by AOBs system, and royalisin was subsequently released from the AOBs through self‐splicing of the intein. The recombinant royalisin exhibited high antibacterial activity, which suggested that it was refolded to its functional structure. These results demonstrated that AOBs system is an efficient method to functionally express and purify small AMPs. In addition, it also provides a facile platform for the production of antibodies against small peptides. © 2010 American Institute of Chemical Engineers Biotechnol. Prog., 2011
Synthesis and biophysical properties of polymerized human serum albumin
Authors: Elmer Jacob , Cabrales Pedro , Wang Qi , Zhang Ning , Palmer Andre F. 
Published: November 2010

AbstractThe use of many plasma expanders (PEs) is often limited by undesirable side effects, such as red blood cell (RBC) aggregation (hydroxyethyl starch), nephrotoxicity (dextran), and extravasation (albumin). Despite its natural prevalence in the bloodstream, human serum albumin (HSA) can increase the risk of mortality when administered to patients with increased vascular permeability (i.e., patients suffering from burns, septic shock, and endothelial dysfunction). The harmful extravasation of HSA can be limited by polymerizing HSA to increase its molecular size. In this study, HSA was nonspecifically cross‐linked with glutaraldehyde at different cross‐link densities by varying the molar ratio of glutaraldehyde to HSA. The results of this study show that the weight‐averaged molecular weight (MW), viscosity, and extent of RBC aggregation of polymerized HSA increases with increasing cross‐link density, whereas the colloid osmotic pressure (COP) decreases with increasing cross‐link density. Interestingly, circular dichroism measurements indicate that the secondary structure of HSA is unaffected by polymerization. Altogether, these results show that glutaraldehyde can effectively cross‐link HSA to produce high MW polymers, yielding a novel series of potential PEs that exhibit low COP and high viscosity. © 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2011
SCAI consensus document on occupational radiation exposure to the pregnant cardiologist and technical personnel
Authors: Best Patricia J. M. , Skelding Kimberly A. , Mehran Roxana , Chieffo Alaide , Kunadian Vijayalakshmi , Madan Mina , Mikhail Ghada W. , Mauri Fina , Takahashi Saeko , Honye Junko , Hernández‐Antolín Rosana , Weiner Bonnie H. ,   for the Society for Cardiovascular Angiography & Interventions' Women in Innovations (WIN) group
Published: November 2010

AbstractConcerns regarding radiation exposure and its effects during pregnancy are often quoted as an important barrier preventing many women from pursuing a career in Interventional Cardiology. Finding the true risk of radiation exposure from performing cardiac catheterization procedures can be challenging and guidelines for pregnancy exposure have been inadequate. The Women in Innovations group of Cardiologists with endorsement of the Society for Cardiovascular Angiography and Interventions aim to provide guidance in this publication by describing the risk of radiation exposure to pregnant physicians and cardiac catheterization personnel, to educate on appropriate radiation monitoring and to encourage mechanisms to reduce radiation exposure. Current data do not suggest a significant increased risk to the fetus of pregnant women in the cardiac catheterization laboratory and thus do not justify precluding pregnant physicians from performing procedures in the cardiac catheterization laboratory. However, radiation exposure among pregnant physicians should be properly monitored and adequate radiation safety measures are still warranted. © 2011 Wiley‐Liss, Inc.
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
Authors: Ilson David H. , Kelsen David , Shah Manish , Schwartz Gary , Levine Douglas A. , Boyd Jeff , Capanu Marinela , Miron Benjamin , Klimstra David 
Published: November 2010

AbstractBACKGROUND:Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer.METHODS:Thirty patients with measurable, metastatic cancer of the esophageal and gastroesophageal junction received 150 mg erlotinib daily. EGFR‐negative tumors (6 patients; 20%) and EGFR‐over expressing tumors (24 patients; 80%) were treated. Most patients were men (70%) with adenocarcinoma (57%) and had received previous chemotherapy (97%).RESULTS:Two partial responses were observe d in the EGFR‐positive cohort (2 of 24 patients; 8%), and no responses were observed in the EGFR‐negative cohort (0 of 6 patients). Reponses were limited to patients who had squamous cell carcinoma (2 of 13 patients; 15%; response duration, 5.5‐7 months). The time to tumor progression was longer in patients who had squamous cell carcinoma (3.3 months; range, 1‐24 months) compared with patients who had adenocarcinoma (1.6 months; range, 1‐6 months; P = .026). Therapy was tolerable with the expected toxicity of skin rash (grade 1‐2, 67%; grade 3, 10%).CONCLUSIONS:Erlotinib had limited activity in patients with esophageal cancer, and responses and some protracted stable disease were observed in those with squamous cell carcinoma. Efficacy according to EGFR status could not be assessed given the rarity of EGFR‐negative tumors. The current results indicated that further evaluation of this agent in squamous cell carcinoma is warranted. Cancer 2011. © 2010 American Cancer Society.
Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy
Authors: Zaanan Aziz , Gauthier Mélanie , Malka David , Locher Christophe , Gornet Jean‐Marc , Thirot‐Bidault Anne , Tougeron David , Taïeb Julien , Bonnetain Franck , Aparicio Thomas ,   for the Association des Gastro Entérologues Oncologues
Published: November 2010

AbstractBACKGROUND:Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced SBA, but data regarding second‐line chemotherapy are lacking. The aim of this study was to evaluate the efficacy and tolerability of fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) as second‐line chemotherapy in patients with advanced SBA.METHODS:We analyzed all consecutive patients who received second‐line chemotherapy with FOLFIRI among 93 patients with advanced SBA included from 1996 to 2008 in a previous retrospective multicenter study. Progression‐free survival (PFS) and overall survival (OS) were estimated from the start of second‐line chemotherapy using the Kaplan‐Meier method. Cox models were applied for multivariate analyses.RESULTS:Among 51 patients who received second‐line chemotherapy, 28 patients (male, 57%; median age, 54 years; metastatic disease, 96%) were treated with FOLFIRI after progression (n = 24) or limiting toxicity (n = 4) to first‐line FOLFOX (n = 19) or LV5FU2‐cisplatin (n = 9). Grade 3‐4 toxicity was observed in 48% of patients (grade 3‐4 neutropenia, 37%). After a median follow‐up of 21.5 months, all patients had tumor progression, and 22 patients died. Objective response rate was 20%, and disease control rate was 52%. Median PFS and OS were 3.2 and 10.5 months, respectively. No clinical, biological, or tumor characteristics were associated with PFS or OS by multivariate analysis.CONCLUSIONS:Second‐line chemotherapy with FOLFIRI produced disease control in half of patients with advanced SBA after failure with first‐line platinum‐based chemotherapy. Nevertheless, the short median PFS warrants the evaluation of other treatments including targeted therapies. Cancer 2011. © 2010 American Cancer Society.
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol
Authors: Kiefer Matthew V. , Albert Marissa , McNally Madeline , Robertson Mary , Sun Weijing , Fraker Douglas , Olthoff Kim , Christians Kathleen , Pappas Sam , Rilling William , Soulen Michael C. 
Published: November 2010

AbstractBACKGROUND:Unresectable intrahepatic cholangiocarcinoma has a poor prognosis, with a median survival of 5 to 8 months without treatment. Response and survival after chemoembolization were evaluated.METHODS:Lobar or segmental chemoembolization with cisplatinum, doxorubicin, mitomycin‐C, ethiodol, and polyvinyl alcohol particles was performed at monthly intervals for 1‐4 sessions until the entire intrahepatic tumor burden was treated. Cross‐sectional imaging and clinical and laboratory evaluation were performed before treatment, 1 month after treatment, and then every 3 months. A second cycle of treatment was performed for intrahepatic recurrence. Toxicity was assessed using NCI CTC v.3.0. Response was evaluated using RECIST criteria, and survival was estimated with Kaplan‐Meier analysis.RESULTS:Sixty‐two patients were treated. Thirty‐seven had pathologically proven cholangiocarcinoma, and 25 had poorly differentiated adenocarcinoma of unknown primary, likely cholangiocarcinoma. One hundred and twenty‐two total procedures were performed during the initial cycle of treatment (mean, 2.0 per patient). Twenty patients received a second cycle, for a total of 165 procedures. There were 5 major complications. Thirty‐day disease‐specific mortality was 0%. Forty‐five of 62 patients were evaluable for morphologic response after completion of their initial cycle: 11% (n = 5) partial responses, 64% (n = 29) stable, and 24% (n = 11) progressed. Median time to progression from first chemoembolization was 8 months, with 28% free of progression at 12 months. Median survival from time of diagnosis was 20 months, with 1‐, 2‐, and 3‐year survival of 75%, 39%, and 17%, respectively. Median survival from time of first chemoembolization was 15 months, with 1‐, 2‐, and 3‐year survival of 61%, 27%, and 8%, respectively. There was no statistically significant difference in survival between patients with cholangiocarcinoma and those with poorly differentiated adenocarcinoma. Patients who also received systemic chemotherapy had improved overall survival (median 28 vs 16 months, P = .02; HR, 1.94; 95% CI, 1.13‐3.33).CONCLUSIONS:Chemoembolization provided local disease control (PR + SD) of intrahepatic cholangiocarcinoma and adenocarcinoma of unknown primary in 76%. Overall survival after chemoembolization showed the best outcomes for those receiving multidisciplinary integrated liver‐directed and systemic therapies. Cancer 2011. © 2010 American Cancer Society.
Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma
Authors: Eigentler Thomas K. , Figl Adina , Krex Dietmar , Mohr Peter , Mauch Cornelia , Rass Knut , Bostroem Azize , Heese Oliver , Koelbl Oliver , Garbe Claus , Schadendorf Dirk ,   on behalf of the Dermatologic Cooperative Oncology Group and the National Interdisciplinary Working Group on Melanoma
Published: November 2010

AbstractBACKGROUND:This multicenter study aimed to identify prognostic factors in patients with brain metastases from malignant melanoma (BM‐MM).METHODS:In a retrospective survey in 9 cancer centers of the German Cancer Society, 692 patients were identified with BM‐MM during the period 1986 through 2007. Overall survival was analyzed using a Kaplan‐Meier estimator and compared with log‐rank analysis. Cox proportional hazards models were used to identify prognostic factors significant for survival.RESULTS:The median overall survival of the entire cohort was 5.0 months (95% confidence interval [95% CI], 4 months‐5 months). Significant prognostic factors in the univariate Kaplan‐Meier analysis were Karnofsky performance status (≥70% vs <70%; P < .001), number of BM‐MM (single vs multiple; P < .001), pretreatment levels of lactate dehydrogenase (LDH) (normal vs elevated; P < .001) and S‐100 (normal vs elevated; P < .001), prognostic groups according to Radiation Therapy Oncology Group (class I vs class II vs class III; P = .0485), and treatment choice (for the cohort with single BM‐MM only) (stereotactic radiotherapy or neurosurgical metastasectomy vs others; P = .036). Cox proportional hazards models revealed pretreatment elevated level of serum LDH (hazard ratio [HR], 1.6; 95% CI, 1.3‐2.0 [P = .00013]) and number of BM‐MM (HR, 1.6; 95% CI, 1.3‐2.0 [P = .00011]) to be independent prognostic variables in the entire cohort, whereas in patients with a single BM‐MM, treatment choice (HR, 1.5; 95% CI, 1.1‐1.9 [P = .0061]) was identified as a unique prognostic factor.CONCLUSIONS:The overall survival of patients with BM‐MM primarily depends on the number of metastases and pretreatment level of LDH. In the case of a single brain metastasis, stereotactic radiotherapy or neurosurgical metastasectomy is by far the most important factor for improving survival. Cancer 2011. © 2010 American Cancer Society.
A phase II trial of nab‐paclitaxel (ABI‐007) and carboplatin in patients with unresectable stage IV melanoma
Authors: Kottschade Lisa A. , Suman Vera J. , Amatruda Thomas , McWilliams Robert R. , Mattar Bassam I. , Nikcevich Daniel A. , Behrens Robert , Fitch Tom R. , Jaslowski Anthony J. , Markovic Svetomir N. 
Published: November 2010

AbstractBACKGROUND:There is increasing evidence that paclitaxel and carboplatin are clinically active in the treatment of metastatic melanoma (MM). ABI‐007 is an albumin‐bound formulation of paclitaxel that has demonstrated single‐agent activity against metastatic melanoma.METHODS:A parallel phase II trial was conducted in patients with unresectable stage IV melanoma who were either chemotherapy naive (CN) or previously treated (PT). The treatment regimen consisted of ABI‐007 (100 mg/m2) and carboplatin area under the curve (AUC2) administered on days 1, 8, and 15 every 28 days. The primary aim of this study was objective response rate (RECIST).RESULTS:Seventy‐six patients (41 CN and 35 PT) were enrolled between November 2006 and July 2007. Three patients withdrew consent prior to starting treatment. The median number of treatment cycles was 4. There were 10 (25.6%) responses (1 complete response [CR] and 9 partial responses [PRs]) in the CN cohort (90% CI, 16.7%‐42.3%) and 3 (8.8%) responses (3 PRs) in the PT cohort (90% CI, 2.5%‐21.3%). Median progression‐free survival was 4.5 months in the CN cohort and 4.1 months in the PT cohort. Median overall survival (OS) was 11.1 months in the CN group and 10.9 months in the PT group. Severe toxicities in both groups (Common Terminology Criteria for Adverse Effects v.3.0 ≥grade 3) included neutropenia, thrombocytopenia, neurosensory problems, fatigue, nausea, and vomiting.CONCLUSIONS:The weekly combination of ABI‐007 and carboplatin appears to be moderately well tolerated, with promising clinical activity as therapy in patients who are chemotherapy naive and with modest antitumor activity in those previously treated. Cancer 2011. © 2010 American Cancer Society.
MicroRNA‐137 promoter methylation is associated with poorer overall survival in patients with squamous cell carcinoma of the head and neck
Authors: Langevin Scott M. , Stone Roslyn A. , Bunker Clareann H. , Lyons‐Weiler Maureen A. , LaFramboise William A. , Kelly Lori , Seethala Raja R. , Grandis Jennifer R. , Sobol Robert W. , Taioli Emanuela 
Published: November 2010

AbstractBACKGROUND:The overall 5‐year survival rate of approximately 60% for head and neck cancer patients has remained essentially unchanged over the past 30 years. MicroRNA‐137 (miR‐137) plays an essential role in cell‐cycle control at the G1/S‐phase checkpoint. However, the aberrantmiR‐137promoter methylation observed in squamous cell carcinoma of the head and neck (SCCHN) suggests a tumor‐specific molecular defect that may contribute to disease progression.METHODS:The goal of this study was to assess, in formalin‐fixed, paraffin‐embedded tumor tissue, the association betweenmiR‐137promoter methylation and survival (both overall and disease free) and with prognostic factors including stage, tumor size, lymph node positivity, tumor grade, and surgical tumor margin positivity.RESULTS:The promoter methylation status ofmiR‐137was ascertained by methylation‐specific polymerase chain reaction and detected in 11 of 67 SCCHN patients (16.4%), with no significant differences according to site (oral cavity, pharynx, larynx). Methylation of themiR‐137promoter was significantly associated with overall survival (hazard ratio, 3.68; 95% confidence interval, 1.01‐13.38) but not with disease‐free survival or any of the prognostic factors evaluated.CONCLUSIONS:The results of this study indicate thatmiR‐137is methylated in tumor tissue from pharyngeal and laryngeal squamous cancers, in addition to oral squamous cell carcinoma, and thatmiR‐137promoter methylation has potential utility as a prognostic marker for SCCHN. Cancer 2011. © 2010 American Cancer Society.
Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer
Authors: Fu Siqing , Hu Wei , Iyer Revathy , Kavanagh John J. , Coleman Robert L. , Levenback Charles F. , Sood Anil K. , Wolf Judith K. , Gershenson David M. , Markman Maurie , Hennessy Bryan T. , Kurzrock Razelle , Bast Robert C. 
Published: November 2010

AbstractBACKGROUND:Sequential treatment with azacitidine can induce re‐expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b‐2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer.METHODS:Patients with pathologically confirmed intermediate‐grade or high‐grade epithelial ovarian cancer who developed disease progression within 6 months (resistant disease, n = 18 patients) or during a platinum‐based therapy (refractory disease, n = 12 patients) were eligible. All patients had measurable disease.RESULTS:Thirty patients received a total of 163 cycles of treatment. This regimen produced 1 complete response, 3 partial responses (overall response rate [ORR], 13.8%), and 10 cases of stable disease among 29 evaluable patients. For those patients who achieved clinical benefits, the median duration of the treatment was 7.5 months. The median progression‐free survival (PFS) and overall survival (OS) for all patients were 3.7 months and 14 months, respectively. Patients with platinum‐resistant disease achieved an ORR of 22%, with a median PFS of 5.6 months and a median OS of 23 months. The predominant toxicities were fatigue and myelosuppression. Correlative studies indicated that DR4 methylation in peripheral blood leukocytes was decreased during treatment in 3 of 4 objective responders (75%), but in only 5 of 13 nonresponders (38%).CONCLUSIONS:To the authors' knowledge, the results of the current study provide the first clinical evidence that a hypomethylating agent may partially reverse platinum resistance in patients with ovarian cancer. Further clinical evaluation of hypomethylating agents in combination with carboplatin is warranted. Cancer 2011. © 2010 American Cancer Society.
Systematic personnel participation for logistics improvement: A case study
Authors: García‐Arca Jesús , Prado‐Prado J. C. 
Published: November 2010

AbstractThe main aim of this paper is to present, in a reasoned and detailed manner, a methodology for Employee Participation System implementation applied in logistics issues. Thus, key aspects are developed in the implementation according to literature, focusing more on the “how” than on the “why.” This methodology is illustrated with the analysis of a case study in the Spanish company GADISA. The participative approach applied in redesigning the processes has been one of the keys to its success, in terms of the efficiency of the actions and in the ease with which they were implemented. Although the main objective of the Employee Participation System was the decision of the Board, the personnel took part in its operational design, from the initial stages of its development, not only proposing improvements but also analyzing, implementing, and supervising alternatives. The proposed methodology may be of interest both in the academic and professional world. © 2010 Wiley Periodicals, Inc.